Docking study of novel designed indazole derivatives against topoisomerase-II DNA gyrase enzyme for antibacterial screening
Nabeela Mareyam , Md Nematullah , Md Faheem Haider , Md Akbar , Md Azizur Rahman
Intelligent Pharmacy ›› 2024, Vol. 2 ›› Issue (2) : 173 -182.
Docking study of novel designed indazole derivatives against topoisomerase-II DNA gyrase enzyme for antibacterial screening
Aim of the study was designed for the design of novel indazole derivatives and evaluation of their docking against topoisomerase-II DNA gyrase enzyme for the antibacterial screening. Different novel substituted indazol-3-yl benzenesulfonamide derivatives were designed for the synthesis from o-chlorobenzonitrile and phenyl hydrazine reaction and further, with benzene sulphonyl chloride reaction. These were evaluated for their docking targeting topoisomerase-II DNA gyrase enzyme for the antibacterial screening. A range of binding affinity (-12.2 to -9.6 kcal/mol) was observed. Compound, 4-chloro-N-(1-phenyl-1H-indazol-3-yl)benzenesulfonamide had the highest binding affinity (-12.2 kcal/mol) which is better than the standard norfloxacin (-10.7 kcal/mol). Compounds (12a, 12c, 12e and 12g) with chloro-substitution at para position of sulfonamide had higher affinity as compared to the compounds (12b, 12d, 12f and 12h) with methyl substitution. A convenient method for the synthesis of indazole derivatives has been developed. 4-chloro-N-(1-phenyl-1H-indazol-3-yl)benzenesulfonamide had shown the best binding affinity. Further, more diverse bioactive moieties may be incorporated into indazole scaffold in the near future by future researchers and a great amount of effort may be dedicated to the exploration of medicinal approaches for their preparation and evaluation of their biological activities.
Docking / Indazole / Pyrazole / Topoisomerase-II / DNA gyrase / Antibacterial
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
2023 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.
/
| 〈 |
|
〉 |